Last reviewed · How we verify
polyphenol
polyphenol is a Small molecule drug developed by University Hospital, Montpellier. It is currently in Phase 1 development.
Polyphenols are a large family of naturally occurring compounds found in plants, including phenolic acids, flavonoids, tannic acid, and ellagitannin. They have been studied in clinical trials for various conditions, including Parkinson's Disease, Overweight, Obesity, Insulin Resistance, and Endothelial Function, using interventions such as Green Tea Polyphenols (EGCG/ECG) and Apple.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | polyphenol |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Berries, Inflammation, and Gut Microbiome (NA)
- Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis (NA)
- Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). (NA)
- Polyphenol Metabotypes in People With Diabetes Type 2
- Impact of Protein Source and Polyphenol Complexation in Protein Bars on Metabolic Health (NA)
- Beetroot Beverage and Repeated Sprint Power Output During RAST (NA)
- Impact of Date Consumption on Metabolic Control and Oxidative Stress in Patients With Type 2 Diabetes (NA)
- Resveratrol for the Prevention of Bone Loss in Postmenopausal Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- polyphenol CI brief — competitive landscape report
- polyphenol updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI
Frequently asked questions about polyphenol
What is polyphenol?
Who makes polyphenol?
What development phase is polyphenol in?
Related
- Manufacturer: University Hospital, Montpellier — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing